CA2789014C - Methods and compositions for improving cognitive function - Google Patents

Methods and compositions for improving cognitive function Download PDF

Info

Publication number
CA2789014C
CA2789014C CA2789014A CA2789014A CA2789014C CA 2789014 C CA2789014 C CA 2789014C CA 2789014 A CA2789014 A CA 2789014A CA 2789014 A CA2789014 A CA 2789014A CA 2789014 C CA2789014 C CA 2789014C
Authority
CA
Canada
Prior art keywords
pharmaceutically acceptable
acceptable salt
oxo
polymorph
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2789014A
Other languages
English (en)
French (fr)
Other versions
CA2789014A1 (en
Inventor
Michela Gallagher
Rebecca Haberman
Ming Teng Koh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of CA2789014A1 publication Critical patent/CA2789014A1/en
Application granted granted Critical
Publication of CA2789014C publication Critical patent/CA2789014C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N57/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Plant Pathology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Hospice & Palliative Care (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2789014A 2010-02-09 2011-02-09 Methods and compositions for improving cognitive function Active CA2789014C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30276010P 2010-02-09 2010-02-09
US61/302,760 2010-02-09
PCT/US2011/024256 WO2011100373A1 (en) 2010-02-09 2011-02-09 Methods and compositions for improving cognitive function

Publications (2)

Publication Number Publication Date
CA2789014A1 CA2789014A1 (en) 2011-08-18
CA2789014C true CA2789014C (en) 2019-01-15

Family

ID=44368107

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2789014A Active CA2789014C (en) 2010-02-09 2011-02-09 Methods and compositions for improving cognitive function

Country Status (9)

Country Link
US (3) US20110212928A1 (enExample)
EP (1) EP2533645B1 (enExample)
JP (6) JP6082250B2 (enExample)
CN (2) CN102905532A (enExample)
AU (1) AU2011215870B2 (enExample)
BR (1) BR112012019923A2 (enExample)
CA (1) CA2789014C (enExample)
EA (2) EA037187B1 (enExample)
WO (1) WO2011100373A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008095221A1 (en) 2007-02-07 2008-08-14 Gosforth Centre (Holdings) Pty Ltd Treatment of adhd
AU2009279372A1 (en) 2008-08-06 2010-02-11 Gosforth Centre (Holdings) Pty Ltd Compositions and methods for treating psychiatric disorders
WO2012109491A1 (en) * 2011-02-09 2012-08-16 The Johns Hopkins University Methods and compositions for improving cognitive function
WO2014078568A1 (en) * 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
AU2018208662B2 (en) * 2012-11-14 2020-07-23 The Johns Hopkins University Methods and Compositions for Treating Schizophrenia
WO2014144663A1 (en) * 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
US20160030391A1 (en) * 2013-03-15 2016-02-04 The Johns Hopkins University Methods and compositions for improving cognitive function
EP2968220B1 (en) * 2013-03-15 2021-05-05 Agenebio, Inc. Methods and compositions for improving cognitive function
NZ738682A (en) 2015-05-22 2022-01-28 Agenebio Inc Extended release pharmaceutical compositions of levetiracetam
WO2022011318A1 (en) * 2020-07-10 2022-01-13 Agenebio, Inc. Combinations of gabaa alpha 5 agonists and sv2a inhibitors and methods of using in the treatment of cognitive impairment
CN113144173A (zh) * 2021-03-04 2021-07-23 上海市精神卫生中心（上海市心理咨询培训中心） 胰岛素样生长因子结合蛋白2在制备治疗成年期应激引起的精神障碍的药物中的应用

Family Cites Families (193)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA529379A (en) * 1952-09-20 1956-08-21 Farbenfabriken Bayer Aktiengesellschaft Phosphonic ester
GB1309692A (en) 1970-02-13 1973-03-14 Ucb Sa N-substituted lactams
GB1039113A (en) 1964-08-06 1966-08-17 Ucb Sa New n-substituted lactams
JP2000319257A (ja) 1969-01-06 2000-11-21 Eisai Co Ltd １−ベンジル−４−［（５，６−ジメトキシ−２−フルオロ−１−インダノン）−２−イル］メチルピペリジン
IT1045043B (it) * 1975-08-13 1980-04-21 Isf Spa Derivati pirrolidinici
BE864269A (fr) * 1977-03-03 1978-06-16 Parke Davis & Co Nouveaux n-(aminoalkyl substitue)-2-oxo-1-pyrrolidine-acetamides et procedes pour les produire
ATE27T1 (de) * 1978-05-08 1981-04-15 Ucb Sa Lactam-n-essigsaeuren und ihre amide, verfahren zu ihrer herstellung und heilmittel, die sie enthalten
US4654370A (en) * 1979-03-12 1987-03-31 Abbott Laboratories Glyceryl valproates
US4372960A (en) * 1980-12-12 1983-02-08 Warner-Lambert Company Quaternary derivatives of N-(substituted-aminoalkyl)-2-oxo-1-pyrrolidine-acetamides as cognition activators
FR2515179A1 (fr) * 1981-07-24 1983-04-29 Hoffmann La Roche Derives de pyrrolidine, leur procede de preparation, les intermediaires pour leur synthese et leur application therapeutique
IL67623A (en) * 1983-01-05 1984-09-30 Teva Pharma 1'-ethoxycarbonyloxyethyl ester of valproic acid,its preparation and pharmaceutical compositions containing it
IL72381A (en) * 1983-07-20 1988-03-31 Sanofi Sa Pharmaceutical composition based on valproic acid
GB8412358D0 (en) * 1984-05-15 1984-06-20 Ucb Sa Pharmaceutical composition
GB8412357D0 (en) * 1984-05-15 1984-06-20 Ucb Sa Pharmaceutical composition
US4668687A (en) * 1984-07-23 1987-05-26 Bristol-Myers Company Psychogeriatric 1-(2-pyrimidinyl)piperazinyl derivatives of 1-pyrrolidin-2-ones
US4913906B1 (en) * 1985-02-28 2000-06-06 Yissum Res Dev Co Controlled release dosage form of valproic acid
IL74497A (en) 1985-03-05 1990-02-09 Proterra Ag Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives
JPS6222785A (ja) * 1985-07-23 1987-01-30 Sanwa Kagaku Kenkyusho:Kk 新規な２−オキソピロリジン化合物及びその塩、その製法並びにこれらを有効成分とする脳機能障害の予防及び治療剤
US4663318A (en) * 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
US4816456A (en) * 1986-10-01 1989-03-28 Summers William K Administration of monoamine acridines in cholinergic neuronal deficit states
NL195004C (nl) * 1987-03-04 2003-11-04 Novartis Ag Fenylcarbamaat bevattend farmaceutisch preparaat.
FI91401C (fi) 1987-03-17 1994-06-27 Hoechst Roussel Pharma Menetelmä terapeuttisesti aktiivisten substituoitujen 9-aminotetrahydroakriinien ja niille läheisten yhdisteiden valmistamiseksi
DE3709230A1 (de) * 1987-03-20 1988-10-06 Desitin Arzneimittel Gmbh Neues calciumsalz der valproinsaeure
IT1225462B (it) 1987-04-03 1990-11-14 Mediolanum Farmaceutici Srl Sali organici di derivati della fisostigmina
US5002955A (en) * 1987-04-23 1991-03-26 Hoechst-Roussel Pharmaceuticals Inc. Fused heteroalkylene quinolinamines and use as cholinergic agents
JP2755403B2 (ja) 1987-05-04 1998-05-20 デイービス、ボニー アルツハイマー病の治療のための化合物
US5187165A (en) 1987-05-15 1993-02-16 Hoechst-Roussel Pharmaceuticals Inc. Memory enhancing and analgesic 1,2,3a,8,8a-hexahydro-3a,8(and 1,3a,8)-di(and tri)methylpyrrolo[2,3-b]indoles
FI95572C (fi) 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
JPS6422883A (en) * 1987-07-17 1989-01-25 Sanwa Kagaku Kenkyusho Co 1-pyrrolidine acetamide derivative, its salt, production thereof and prophylactic and remedial agent for cereral dysfunction containing said derivative and salt as active ingredient
ATE68346T1 (de) * 1987-07-22 1991-11-15 Farvalsa Ag Feuchtigkeitsstabile feste valproinsaeurezubereitung und verfahren zu ihrer herstellung.
US4950658A (en) * 1988-12-06 1990-08-21 Board Of Trustees Of Southern Illinois Univ. Method of medical treatment of Alzheimer's disease
FR2643556B1 (fr) * 1989-02-27 1993-03-05 Sanofi Sa Composition pharmaceutique a liberation prolongee d'acide valproique
EP0403713A1 (en) 1989-06-22 1990-12-27 Merrell Dow Pharmaceuticals Inc. Novel acetylcholinesterase inhibitors
US5693668A (en) 1989-06-22 1997-12-02 Merrell Pharmaceuticals Inc. Acetylcholinesterase inhibitors
IT1231477B (it) * 1989-07-12 1991-12-07 Sigma Tau Ind Farmaceuti (pirrolidin-2-one-1-il) acetammidi quali attivatori dei processi di apprendimento e della memoria e composizioni farmaceutiche comprendenti tali composti
US4999430A (en) 1989-07-31 1991-03-12 Warner-Lambert Company Derivatives of 1,2,3,4-tetrahydro-9-acrisinamine
DE3927049A1 (de) 1989-08-16 1991-02-21 Sandoz Ag Halogenalkyl-phenyl-ketone und deren hydrate, ihre herstellung und verwendung
US5387590A (en) 1989-08-30 1995-02-07 Pfizer Inc. Benzazabicyclic carbamates as novel cholinesterase inhibitors
US4914102A (en) * 1989-09-28 1990-04-03 Hoechst Roussel Pharmaceuticals, Inc. N-aminocarbamates related to physostigmine, pharmacentical compositions and use
NZ237241A (en) * 1990-03-02 1993-11-25 Pharmetrix Corp Method for increasing the storage stability of physostigmine
EP0445095A1 (en) 1990-03-02 1991-09-04 Uni Patent Ab Equipment for preventing separation in bulk materials
JP2807577B2 (ja) 1990-06-15 1998-10-08 エーザイ株式会社 環状アミド誘導体
US5102891A (en) 1990-07-23 1992-04-07 Hoechst-Roussel Pharmaceuticals Inc. 1-(substituted pyridinylamino)-1H-indol-5-yl substituted carbamates
US5264442A (en) * 1990-08-13 1993-11-23 Hoechst-Roussel Pharmaceuticals Incorporated Carbamoyl-1-(pyridinylalkyl)-1H-indoles, indolines and related analogs
TW200462B (enExample) 1990-09-27 1993-02-21 Hoechst Roussel Pharma
US5190951A (en) 1990-10-19 1993-03-02 Ss Pharmaceutical Co., Ltd. Quinoline derivatives
JP2965675B2 (ja) 1990-11-21 1999-10-18 エーザイ株式会社 （―）―１―ベンジル―４―〔（５，６―ジメトキシ―１―インダノン）―２―イル〕メチルピペリジンの製造方法
TW197435B (enExample) 1990-11-22 1993-01-01 Takeda Pharm Industry Co Ltd
US5668117A (en) 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US5334720A (en) 1991-03-07 1994-08-02 Fisons Corporation Diphenyl-1-(aminoalkyl)-2-piperidinone and -2-pyrrolidinone derivatives having anticonvulsant properties
ES2188584T3 (es) 1991-03-28 2003-07-01 Eisai Co Ltd Derivados heterociclicos de amina.
US5750542A (en) 1993-09-28 1998-05-12 Pfizer Benzisoxazole and benzisothizole derivatives as cholinesterase inhibitors
US5104880A (en) 1991-05-01 1992-04-14 Mayo Foundation For Medical Education And Research Huperzine a analogs as acetylcholinesterase inhibitors
SK279285B6 (sk) * 1991-05-02 1998-09-09 Daiichi Pharmaceutical Co. Použitie n-(2,6-dimetylfenyl)-2-(2-oxo-1-pyrolidin
FR2677019B1 (fr) 1991-05-27 1994-11-25 Pf Medicament Nouvelles piperidines disubstituees-1,4, leur preparation et leur application en therapeutique.
US5106856A (en) * 1991-06-07 1992-04-21 Hoechst-Roussel Pharmaceuticals Inc. [(Arylalkylpiperidin-4-yl)methyl]-2a,3,4,5-tetrahydro-1(2H)-acenaphthylen-1-ones and related compounds
FR2679555B1 (fr) 1991-07-25 1993-11-19 Fabre Medicament Pierre Nouveaux derives de l'uree, leur preparation et leur application en therapeutique.
CA2113115A1 (en) 1991-07-29 1993-02-18 Vlad E. Gregor Quinazoline derivatives as acetylcholinesterase inhibitors
IT1251166B (it) 1991-08-09 1995-05-04 Chiesi Farma Spa Derivati di geneserina,loro preparazione e composizioni farmaceutiche che li contengono
US5246947A (en) * 1991-09-23 1993-09-21 Hoechst-Roussel Pharmaceuticals Incorporated Substituted pyridinylamino-1,2-benzisothiazoles and their use for treating depression
US5231093A (en) * 1991-10-01 1993-07-27 Hoechst-Roussel Pharmaceuticals Incorporated Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs
TW263504B (enExample) 1991-10-03 1995-11-21 Pfizer
ES2042384B1 (es) 1991-12-26 1994-06-01 Boehringer Ingelheim Espana Procedimiento para obtener derivados bis-piridinicos.
EP0619814A1 (en) 1991-12-31 1994-10-19 Fujisawa Pharmaceutical Co., Ltd. Oxadiazole derivatives having acetylcholinesterase-inhibitory and muscarinic agonist activity
AU4275793A (en) 1992-02-25 1993-09-13 Warner-Lambert Company Cytoprotective compositions containing pyruvate and antioxidants
US5439930A (en) * 1992-04-14 1995-08-08 Russian-American Institute For New Drug Development Biologically active n-acylprolydipeptides having antiamnestic, antihypoxic and anorexigenic effects
IT1254996B (it) * 1992-06-25 1995-10-11 Mediolanum Farmaceutici Srl Esteri amminoalchilcarbammici dell'eserolina atti all'impiego come anticolinesterasici e relativo procedimento di preparazione
US5440023A (en) * 1992-09-18 1995-08-08 Beckman Instruments, Inc. Method for making valproic acid derivatives
EP0611769A1 (en) 1993-02-16 1994-08-24 Merrell Dow Pharmaceuticals Inc. Silylated acetylcholinesterase inhibitors
AU4982293A (en) 1993-03-02 1994-09-26 Fujisawa Pharmaceutical Co., Ltd. Novel heterocyclic compound
EP0627400A1 (en) 1993-06-04 1994-12-07 Merrell Dow Pharmaceuticals Inc. Aromatic acetylcholinesterase inhibitors
SE9302080D0 (sv) 1993-06-16 1993-06-16 Ab Astra New compounds
GB9319732D0 (en) * 1993-09-24 1993-11-10 Ucb Sa Use of (s)-alpha-ethyl-2-oxo-l-pyrrolidineacetamide for the treatment of anxiety
US5468733A (en) 1993-09-30 1995-11-21 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5744476A (en) 1994-06-27 1998-04-28 Interneuron Pharmaceuticals, Inc. Dopamine D1 agonists for the treatment of dementia
US5516759A (en) * 1994-12-08 1996-05-14 Tap Holdings Inc. LHRH antagonists having lactam groups at the N-terminus
US5603176A (en) 1995-02-27 1997-02-18 Hasbro, Inc. Simulated suspended animation biosphere
IL118279A (en) 1995-06-07 2006-10-05 Abbott Lab Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission
IL115113A (en) 1995-08-31 2002-11-10 Israel State 3-carbamoyloxy pyridinium derivatives and pharmaceutical compositions containing them
ES2100129B1 (es) 1995-10-11 1998-02-16 Medichem Sa Nuevos compuestos aminopiridinicos policiclicos inhibidores de acetilcolinesterasa, procedimiento para su preparacion y su utilizacion.
ES2197255T3 (es) 1995-11-17 2004-01-01 MERCK & CO. INC. Nuevos compuestos de arilo sustituido utiles como moduladores de los receptores de acetilcolina.
US5783584A (en) 1995-12-11 1998-07-21 Mayo Foundation For Medical Education And Research THA analogs useful as cholinesterase inhibitors
GB9606736D0 (en) 1996-02-19 1996-06-05 Shire International Licensing Therapeutic method
EP0892796B1 (en) 1996-04-12 2001-10-24 Aventis Pharmaceuticals Inc. Isatin derivatives as acetylcholinesterase inhibitors and analgesics
WO1997046526A1 (en) 1996-06-07 1997-12-11 Eisai Co., Ltd. Stable polymorphs of donepezil (1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine) hydrochloride and process for production
TW513409B (en) 1996-06-07 2002-12-11 Eisai Co Ltd Polymorphs of donepezil hydrochloride
CA2180703A1 (en) 1996-07-08 1998-01-09 Paul Marie Victor Gilis Fast-dissolving galanthamine hydrobromide tablet
AU4078997A (en) 1996-08-22 1998-03-06 New York University Cholinesterase inhibitors for treatment of parkinson's disease
IT1285801B1 (it) * 1996-10-10 1998-06-24 Sigma Tau Ind Farmaceuti Procedimento migliorato per la preparazione dell'acido valproico
AU5716898A (en) 1997-01-08 1998-08-03 Warner-Lambert Company Acetylcholinesterase inhibitors in combination with muscarinic agonists for the treatment of alzheimer's disease
DK0971713T3 (da) 1997-03-03 2003-09-22 Eisai Co Ltd Anvendelse af cholinesteraseinhibitorer til behandling af opmærksomhedsforstyrrelser
GB9716879D0 (en) 1997-08-08 1997-10-15 Shire Int Licensing Bv Treatment of attention deficit disorders
AU8742198A (en) 1997-08-15 1999-03-08 Shire International Licensing B.V. Use of cholinesterase inhibitor for treating diseases associated with pro teolytic enzyme activity
US6479523B1 (en) 1997-08-26 2002-11-12 Emory University Pharmacologic drug combination in vagal-induced asystole
EP1048653B1 (en) 1997-12-05 2004-03-03 Eisai Co., Ltd. Donepezil polycrystals and process for producing the same
US6131106A (en) * 1998-01-30 2000-10-10 Sun Microsystems Inc System and method for floating-point computation for numbers in delimited floating point representation
GB9805561D0 (en) 1998-03-16 1998-05-13 Merck Sharp & Dohme A combination of therapeutic agents
US6262081B1 (en) 1998-07-10 2001-07-17 Dupont Pharmaceuticals Company Composition for and method of treating neurological disorders
US6218383B1 (en) 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
IL125809A (en) 1998-08-17 2005-08-31 Finetech Lab Ltd Process and intermediates for production of donepezil and related compounds
IT1304904B1 (it) 1998-09-11 2001-04-05 Eisai Co Ltd Derivati anticolinesterasici per il trattamento delle sindromidolorose funzionali e/o organiche
IL142588A0 (en) 1998-10-16 2002-03-10 Janssen Pharmaceutica Nv Therapy for improving cognition
AU1738800A (en) 1998-11-23 2000-06-13 Bonnie Davis Dosage formulations for acetylcholinesterase inhibitors
ATE306264T1 (de) 1998-12-11 2005-10-15 Bonnie M Davis Verwendung von acetylcholinesterase inhibitoren zur modulierung der hypothalamus-hypophysen- gonadenachse
US6277866B1 (en) * 1999-03-03 2001-08-21 Eisai Co., Ltd. 1-benzyl-4[(5,6-dimethoxy-2-fluoro-1-indanon)-2-yl]methylpiperidine
JP4242032B2 (ja) 1999-03-03 2009-03-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 ４−置換ピペリジン誘導体フッ化物
ES2211056T3 (es) 1999-03-31 2004-07-01 Eisai Co., Ltd. Composiciones estabilizadas que contienen farmacos nootropicos.
EP1050303A3 (en) 1999-04-27 2003-01-15 Pfizer Products Inc. Methods and compositions for treating age-related behavioral disorders in companion animals
US6524616B1 (en) 1999-06-25 2003-02-25 Wake Forest University Health Services Compositions and methods for treating or preventing neurodegeneration and cognitive decline and dysfunction associated with alzheimer's disease, aging, other dementia related disorders and estrogen deficiency related conditions
JP4242048B2 (ja) 1999-09-01 2009-03-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 ４−置換ピペリジン誘導体
CN1167682C (zh) 1999-09-22 2004-09-22 先灵公司 毒蕈碱拮抗剂
GB0004297D0 (en) 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
WO2001066114A1 (en) 2000-03-03 2001-09-13 Eisai Co., Ltd. Novel methods using cholinesterase inhibitors
US20030144255A1 (en) 2000-03-06 2003-07-31 Bain Allen I Compositions for prevention and treatment of dementia
US6706741B2 (en) 2000-04-13 2004-03-16 Eisai Co., Ltd. Acetylcholinesterase inhibitors containing 1-benzyl-pyridinium salts
US20010036949A1 (en) 2000-05-09 2001-11-01 Coe Jotham Wadsworth Pharmaceutical composition and method of treatment of diseases of cognitive dysfunction in a mammal
US6756385B2 (en) * 2000-07-31 2004-06-29 Pfizer Inc. Imidazole derivatives
US20020151591A1 (en) 2000-10-17 2002-10-17 Anabella Villalobos Combination use of acetylcholinesterase inhibitors and GABAa inverse agonists for the treatment of cognitive disorders
CN1484527A (zh) * 2000-12-28 2004-03-24 ��һ��������ҩ��ʽ���� 神经性疼痛治疗和预防药
US6610326B2 (en) * 2001-02-16 2003-08-26 Andrx Corporation Divalproex sodium tablets
JP2004523557A (ja) * 2001-02-23 2004-08-05 ジョンズ・ホプキンス・ユニバーシティ チック、振せん、および関連疾患の治療
EP1372620A2 (en) 2001-03-15 2004-01-02 Saegis Pharmaceuticals Methods for restoring cognitive function following systemic stress
DE60208630T2 (de) * 2001-05-11 2006-08-17 Pfizer Products Inc., Groton Thiazolderivate und ihre Verwendung als cdk-Inhibitoren
EP1395560A1 (en) 2001-05-23 2004-03-10 Ucb, S.A. 2-oxo-piperidinyl- and 2-oxo-azepanyl alkanoic acid derivativ es for the treatment of epilepsy and other neurological disorders
US8354438B2 (en) 2001-08-08 2013-01-15 Michael Chez Neurological functions
US20040192759A1 (en) * 2001-08-22 2004-09-30 Eiichi Otomo Use of nefiracetam for treating neurodegeneration
WO2003020289A1 (en) 2001-08-30 2003-03-13 Ortho-Mcneil Pharmaceutical, Inc. Treatment of dementia and memory disorders with anticonvulsants and acetylcholinesterase inhibitors
US6495700B1 (en) 2002-01-09 2002-12-17 Axonyx, Inc. Process for producing phenserine and its analog
US6759552B2 (en) 2002-03-28 2004-07-06 Council Of Scientific And Industrial Research Compound as cholinesterase inhibitor and its isolation from fungus sporotrichum species
WO2003082820A1 (en) 2002-03-29 2003-10-09 Eisai Co., Ltd. (1-indanone)-(1,2,3,6-tetrahydropyridine) derivative
ES2315494T3 (es) 2002-04-26 2009-04-01 Schering Corporation Antagonistas muscarinicos.
AU2003298514A1 (en) 2002-05-17 2004-05-04 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
EP1509232B1 (en) 2002-05-31 2008-11-19 H. Lundbeck A/S A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease
US20040116506A1 (en) * 2002-06-20 2004-06-17 Krusz John Claude Use of levetiracetam for treating or preventing acute headaches
US7557137B2 (en) * 2002-08-05 2009-07-07 Bristol-Myers Squibb Company Gamma-lactams as beta-secretase inhibitors
US7635709B2 (en) 2002-09-26 2009-12-22 The United States Of America As Represented By The Department Of Veterans Affairs Compositions and methods for bowel care in individuals with chronic intestinal pseudo-obstruction
GB0223494D0 (en) 2002-10-09 2002-11-13 Neuropharma Sa Dual binding site acetylcholinesterase inhibitors for the treatment of alzheimer's disease
AU2003274353B2 (en) * 2002-10-24 2007-04-05 Merz Pharma Gmbh & Co. Kgaa Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
NZ540288A (en) 2002-11-22 2009-06-26 Univ Johns Hopkins Target for therapy of cognitive impairment
US7090985B2 (en) * 2002-12-03 2006-08-15 Ucb, S.A. Methods for the identification of agents for the treatment of seizures, neurological diseases, endocrinopathies and hormonal diseases
WO2004051222A2 (en) * 2002-12-03 2004-06-17 Ucb, S.A. Methods for the identification of agents for the treatment of seizures, neurological diseases, endocrinopathies and hormonal diseases
WO2004052348A2 (en) 2002-12-11 2004-06-24 Pharmacia & Upjohn Company Llc Treatment of diseases with combinations of alpha 7 nicotinic acetylcholine receptor agonists and other compounds
MXPA05009435A (es) 2003-03-06 2005-11-23 Celgene Corp Metodos de uso y composiciones que contienen medicamentos inhibidores selectivos de citocina para el tratamiento y manejo de alteraciones del sistema nervioso central.
ITMI20030573A1 (it) * 2003-03-24 2004-09-25 Nikem Research Srl Composti ad azione nootropica, loro preparazione,
US20040191334A1 (en) 2003-03-24 2004-09-30 Pang-Chui Shaw Use of transhinone derivates as cholinesterase inhibitors in treating related diseases
TW200508197A (en) 2003-03-31 2005-03-01 Ucb Sa Indolone-acetamide derivatives, processes for preparing them and their uses
US7732162B2 (en) * 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
AR044152A1 (es) * 2003-05-09 2005-08-24 Bayer Corp Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad
GB0322140D0 (en) 2003-09-22 2003-10-22 Pfizer Ltd Combinations
EP2269608A3 (en) 2003-10-16 2011-02-16 NeuroSearch AS Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an acetylcholinesterase inhibitor
JP4676961B2 (ja) 2003-10-21 2011-04-27 コルシド・ファーマシューティカルズ・インコーポレイテッド コリンエステラーゼを阻害し、薬理活性物質を放出するカルバモイルエステル類
WO2005054188A1 (en) 2003-12-02 2005-06-16 Ucb, S.A. Imidazole derivatives, processes for preparing them and their uses
US20050222123A1 (en) 2004-01-27 2005-10-06 North Shore-Long Island Jewish Research Institute Cholinesterase inhibitors for treating inflammation
WO2005074535A2 (en) 2004-01-30 2005-08-18 Eisai Co., Ltd. Cholinesterase inhibitors for spinal cord disorders
US20050182044A1 (en) 2004-02-17 2005-08-18 Bruinsma Gosse B. Combinatorial therapy with an acetylcholinesterase inhibitor and (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3,-b]indol-5-yl phenylcarbamate
US20070213388A1 (en) 2004-03-19 2007-09-13 Bruinsma Gosse B Acetylcholinesterase Inhibitors and N-Methyl-D-Aspartate Antagonists Useful in the Treatment of of Cognitive Disorders
WO2006034196A1 (en) * 2004-09-17 2006-03-30 Lifelike Biomatic Inc. Compositions for enhancing memory and methods therefor
US9186345B2 (en) 2004-10-12 2015-11-17 Hakon Hakonarson Method of treating skin diseases
WO2006060082A1 (en) 2004-10-22 2006-06-08 THE GOVERNMENT OF THE U.S.A. as represented by THE SEC., DEPT. OF HEALTH & HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH Tricyclic compounds, preparation thereof and use thereof as cholinesterase activity inhibitors
WO2006071274A2 (en) 2004-12-23 2006-07-06 Voyager Pharmaceutical Corporation Leuprolide acetate and acetylcholinesterase inhibitors or nmda receptor antagonists for the treatment of alzheimer’s disease
WO2006070394A1 (en) 2004-12-28 2006-07-06 Council Of Scientific And Industrial Research Substituted carbamic acid quinolin-6-yl esters useful as acetylcholinesterase inhibitors
WO2006076569A2 (en) * 2005-01-12 2006-07-20 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
FR2881618B1 (fr) 2005-02-10 2007-04-13 Centre Nat Rech Scient Utilisation de composes derives de pyrimidinetrione en tant qu'inhibiteurs de l'acetylcholinesterase, compositions contenant ces derives et leurs utilisations en tant qu'insecticides
WO2006102750A1 (en) * 2005-03-30 2006-10-05 Genpharm Inc. Combined-step process for pharmaceutical compositions
JP5666087B2 (ja) * 2005-04-06 2015-02-12 アダマス・ファーマシューティカルズ・インコーポレーテッド Ｃｎｓ関連疾患の治療のための方法及び組成物
JP2008542323A (ja) 2005-06-01 2008-11-27 ユセベ ファルマ ソシエテ アノニム ２−オキソ−１−ピロリジン誘導体、その製造方法及びその使用
EP1731149A1 (en) * 2005-06-08 2006-12-13 Ucb S.A. Use of 2-oxo-1-pyrrolidone derivatives for the treatment of diseases characterized by progressive myoclonic epilepsy
EP2682481A3 (en) 2005-08-03 2014-09-17 The Johns-Hopkins University Methods for characterizing and treating cognitive impairment in aging and disease
GB0517740D0 (en) * 2005-08-31 2005-10-12 Novartis Ag Organic compounds
US20090018148A1 (en) * 2005-12-07 2009-01-15 Ucb Pharma, S.A. Xanthine Derivatives, Processes For Preparing Them And Their Uses
US20100216734A1 (en) * 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2001463B1 (en) 2006-03-20 2013-07-03 Council of Scientific and Industrial Research A pharmaceutical composition useful as acetyl cholinesterase inhibitors
WO2007127474A2 (en) 2006-04-28 2007-11-08 Northwestern University Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
WO2007134077A2 (en) * 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
US7858611B2 (en) * 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
US20080014271A1 (en) * 2006-07-13 2008-01-17 Ucb, S.A. Novel pharmaceutical compositions comprising levetiracetam
WO2008021666A2 (en) * 2006-08-18 2008-02-21 Morton Grove Pharmaceuticals, Inc. Stable liquid levetiracetam compositions and methods
US20080103105A1 (en) * 2006-09-22 2008-05-01 Braincells, Inc. HMG CoA REDUCTASE MEDIATED MODULATION OF NEUROGENESIS
BRPI0718437A2 (pt) 2006-10-27 2013-11-19 Medivation Neurology Inc Métodos e terapias de combinação para tratar a doença de alzheimer usando, entre outros, dimebon e dolepezil
EP2114166A4 (en) 2006-12-11 2011-05-25 Reviva Pharmaceuticals Inc COMPOSITIONS, SYNTHESIS, AND METHODS OF USING INDANONE-BASED CHOLINESTERASE INHIBITORS
WO2008074896A1 (en) 2006-12-21 2008-06-26 Prendergast Patrick T Compositions and methods for treatment of chronic neurological disorders
MX2009008288A (es) 2007-02-02 2009-12-01 Colucid Pharmaceuticals Inc Compuestos que inhiben la colinesterasa.
WO2008095221A1 (en) * 2007-02-07 2008-08-14 Gosforth Centre (Holdings) Pty Ltd Treatment of adhd
WO2008132142A2 (en) 2007-04-27 2008-11-06 Ucb Pharma S.A. New heterocyclic derivatives useful for the treatment of cns disorders
US7846930B2 (en) 2007-05-18 2010-12-07 Janssen Pharmaceutica Nv Diaryl-substituted tetrahydroisoquinolines as histamine H3 receptor and serotonin transporter modulators
RU2339620C1 (ru) 2007-07-09 2008-11-27 Общество С Ограниченной Ответственностью "Фармвинг" Оксалат n, n-диметил-2-n, n-диметиламинометилпиридил-3-карбамат, обладающий антихолинэстеразной активностью и способностью улучшать когнитивные функции
EP2164489A2 (en) * 2007-07-13 2010-03-24 Eisai R&D Management Co., Ltd. Combination of ampa receptor antagonists and acetylcholinesterase inhibitors for the treatment of neuropathic pain
US20090176740A1 (en) * 2007-11-30 2009-07-09 Phillips Ii Dauglas James Treatment of neurological conditions by the co-administration of aniracetam and l-alpha glycerylphosphorylcholine
US20110212944A1 (en) 2008-07-01 2011-09-01 Julie Liu 2-oxo-1-pyrrolidine derivatives
US9125898B2 (en) * 2008-11-14 2015-09-08 Neurotune Ag Acetam derivatives for pain relief
US20100125094A1 (en) 2008-11-17 2010-05-20 Auspex Pharmaceuticals, Inc. Pyrrolidinyl modulators of nicotinic acetylcholine receptors
US20100172979A1 (en) * 2008-12-24 2010-07-08 Zhongshui Yu Controlled-release formulations
US8846411B2 (en) 2009-06-11 2014-09-30 Microgenics Corporation Derivatives, reagents, and immunoassay for detecting levetiracetam

Also Published As

Publication number Publication date
JP2018008993A (ja) 2018-01-18
US20110212928A1 (en) 2011-09-01
JP6082250B2 (ja) 2017-02-15
EA201290764A1 (ru) 2014-01-30
CN102905532A (zh) 2013-01-30
EA202092673A2 (ru) 2021-03-31
AU2011215870B2 (en) 2016-01-28
AU2011215870A1 (en) 2012-08-23
EP2533645A4 (en) 2013-05-29
EA037187B1 (ru) 2021-02-17
JP2020172552A (ja) 2020-10-22
US20180015109A1 (en) 2018-01-18
JP2015187179A (ja) 2015-10-29
EA202092673A3 (ru) 2021-05-31
US20220265685A1 (en) 2022-08-25
JP2022044797A (ja) 2022-03-17
WO2011100373A1 (en) 2011-08-18
EP2533645A1 (en) 2012-12-19
CN109662964A (zh) 2019-04-23
EP2533645B1 (en) 2016-07-27
CA2789014A1 (en) 2011-08-18
JP2013518914A (ja) 2013-05-23
JP2018138618A (ja) 2018-09-06
JP7057075B2 (ja) 2022-04-19
BR112012019923A2 (pt) 2016-08-09

Similar Documents

Publication Publication Date Title
AU2021200325B2 (en) Methods and compositions for improving cognitive function
CA2891122C (en) Methods and compositions for treating schizophrenia
CA2904767C (en) Methods and compositions for improving cognitive function
EP2533645B1 (en) Methods and compositions for improving cognitive function
WO2014144663A1 (en) Methods and compositions for improving cognitive function
WO2014144546A1 (en) Methods and compositons for improving cognitive function
HK40003608A (en) Methods and compositions for improving cognitive function
HK1261244A1 (en) Levetiracetam for improving cognitive function
HK1192821A (en) Methods and compositions for improving cognitive function
HK1179475A (en) Methods and compositions for improving cognitive function
HK1179475B (en) Methods and compositions for improving cognitive function
AU2013344646A1 (en) Methods and compositions for treating schizophrenia

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160208

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251020

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260202

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260205

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260323